An intervention program powered by artificial intelligence (AI) and data collected by wearable sensors was linked to a type 2 diabetes (T2D) remission rate of more than 80%, according to a new study presented at the 82nd Scientific Sessions of the American Diabetes Association (ADA) in New Orleans, LA.
Researchers conducted a multicenter, randomized controlled trial to determine the effect of Twin Precision Treatment technology (TPT) vs standard care (SC) on change in HbA1c and T2D remission at 90-day intervals, in addition to multiple secondary endpoints (eg, body mass index, HbA1c, time in range).
The TPT intervention used the Whole Body Digital Twin™ platform to integrate multi-dimensional data to give more precise nutrition and health recommendations via the Whole Body Digital Twin app and by coaches. The Whole Body Digital Twin platform was developed by Twin Health and uses both AI and the Internet of Things, along with wearable sensors such as glucose monitors and fitness watches, to collect thousands of digital health data points daily.
“Our results demonstrate the potential of Whole Body Digital Twin technology to change the conventional, medication-driven management of type 2 diabetes to achieving remission of type 2 diabetes with a life free of medication,” said presenting author Paramesh Shamanna, MD, who is a full-time employee for Twin Health, in an ADA press release. “The impact of the program on patient satisfaction, quality of life, and total cost of care is substantial and holds significant promise for large populations suffering from metabolic disease globally.
The baseline mean age, T2D duration, and HbA1c obtained in 319 adults with T2D were 45 years, 3.9 years, and 9.0%, respectively, according to the study abstract. Interim analysis of 262 patients (TPT, n=199; SC, n=63) who reached 180 days showed 94.9% of TPT patients had an HbA1c of <6.5% on no medications or metformin only; 83.9% achieved T2D remission based on ADA criteria. All 9 insulin-using participants stopped insulin before 90 days, added investigators.
Results showed significant improvement in secondary endpoints in the TPT cohort from baseline to 180 days, including HbA1c (9.0% to 5.7%; P<.001). Also, the 3.3% HbA1c reduction in the TPT group was greater than the 0.39% reduction in the SC group (P<.0001).
Shamanna et al noted that future long-term studies are needed to support these initial findings.
Reference: Shamanna P, Shah L, Mohammed J, et al. Remission of type 2 diabetes and improvement in metabolic markers with the twin precision treatment technology (TPT)—A multicenter, randomized, controlled trial. Diabetes. Published online June 1, 2022. DOI: 10.2337/db22-4-LB.